Pharmapack 2025 Insights Overview

CONFERENCE SHOWCASE

As the pharmaceutical world gears up for Pharmapack Europe 2025, held January 22-23 at Paris Expo, Porte de Versailles, three industry leaders share their perspectives on trends shaping the future of drug delivery and packaging. The event, which attracts 6,000 attendees and 400 exhibitors, will feature 70+ sessions addressing critical topics in pharma innovation.

Device Connectivity: Transforming Lives

Alper Hulusi, Head of Market Insights at Clarimed, highlights the growing focus on device connectivity, which he describes as a major trend that enhances clinical outcomes and quality of life. “For individuals with conditions like Type 1 Diabetes, devices that monitor glucose levels automatically and transmit data to healthcare teams are life-changing. This connectivity facilitates better data utilization, optimizing care and management strategies.” Sustainability in device design and manufacturing is another enduring focus, with efforts to improve recyclability and reduce environmental impact. Hulusi will expand on these themes in his Lightning Talk, Designing for an Emergency.

Drug Delivery Evolution

Chris Hurlstone, Director of Drug Delivery at Team Consulting, identifies significant growth in advanced drug delivery technologies, particularly for cell and gene therapies and GLP-1 blockbusters, while small molecule-based formulations continue to dominate. Therapy areas such as oncology, immunology, cardiovascular diseases, and cell and gene therapy are key targets for innovation.

Hurlstone emphasizes that while oral drug formulations still command 90% of the global market, injectables and respiratory delivery systems remain critical for medications unsuitable for oral delivery. These include pre-filled syringes, auto-injectors, and inhalers, among others. Team Consulting’s Alastair Willoughby will delve into innovations in injectables and inhalers during a dedicated session, exploring the intersection of sustainability and innovation.

Balancing Access and Sustainability

Addressing the industry’s sustainability challenge, Willoughby underscores the importance of tailored delivery mechanisms. “A wider range of delivery options—such as prefilled syringes or reusable devices—can address both cost and sustainability concerns. Reusable pen injectors, for instance, may last years, but they have a larger manufacturing carbon footprint than standalone syringes. Personalized solutions can bridge patient needs with environmental goals, reducing carbon footprints and supporting access to essential medicines.”

For more insights, CPHI Frankfurt 2025 (October 28-30, 2025) and the CPHI Annual Report 2024 will further explore industry challenges and opportunities: www.cphi.com/europe.

Learn more about Pharmapack Europe 2025 and its agenda at the heart of pharma innovation: www.pharmapackeurope.com .